In a report released yesterday, Liisa Bayko from Evercore ISI maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), with ...

BofA raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $567 from $555 and keeps a Buy rating on the shares. After having ...

Vertex is ending work on one of its two clinical-stage islet cell treatments after the diabetes therapy looked unlikely to ...

It was nearly 11pm on Thursday night by the time Rangers put Fenerbahce to bed in the Europa League last-16. Some sore heads and tired eyes on Friday morning, then, as Jack Butland’s penalty shoot-out ...

Vertex Pharmaceuticals generated more than $11 billion in product revenue last year thanks to its dominance in cystic fibrosis treatment. Progress in that specialty area and two key drug approvals ...

Forbes contributors publish independent expert analyses and insights. I write on the human/political issues surrounding college admissions.

SCOT capturing the first image of the city of Buenos Aires in South America glowing against the planet's curvature.

MORNING LOWS IN THE 50S AND 60S WARMING UP NICELY ON THURSDAY AN The College Board experienced a glitch that impacted SAT test administrations nationwide today, including sessions at Martin County ...

Since that final, Zverev's form has not improved. He has suffered early defeats in subsequent tournaments, including losses to lower-ranked players. In Buenos Aires, he fell to Francisco Cerundolo, ...

Journavx works differently than other available medications, and its developer, the biotechnology juggernaut Vertex Pharmaceuticals, has positioned it as an important, non-opioid option for pain ...